Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Get Free Report) was the target of a significant decrease in short interest in May. As of May 29th, there was short interest totaling 39,018 shares, a decrease of 73.7% from the May 14th total of 148,551 shares. Based on an average daily trading volume, of 4,357,454 shares, the days-to-cover ratio is currently 0.0 days.
Lakewood-Amedex Biotherapeutics Trading Up 6.2%
LABT stock traded up $0.04 during midday trading on Friday, hitting $0.77. The company had a trading volume of 299,775 shares, compared to its average volume of 2,963,649. Lakewood-Amedex Biotherapeutics has a 52 week low of $0.59 and a 52 week high of $9.82.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen lowered Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th.
Lakewood-Amedex Biotherapeutics Company Profile
We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.
Featured Stories
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
